Human cGAS-DNA Complex Structure and Regulatory Mechanisms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of cGAS function is limited by the lack of structural information for activated human cGAS bound to DNA, hindering the development of effective therapeutics, as existing structures are derived from inactive forms and mammalian homologs, which cannot explain human-specific regulatory controls.
Innovation Solution
Elucidation of the structure of human cGAS in an active conformation bound to DNA and identification of human-specific regulatory mechanisms, specifically through amino acid substitutions at positions K187 and L195, to enhance DNA-sensing specificity and sensitivity, enabling structure-guided therapeutic design.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If structural information is derived from inactive human cGAS or mammalian homologs, then existing structural data can be obtained, but the ability to explain human-specific regulatory controls and guide therapeutic design is compromised
Solution Approach 1:
The patent performs preliminary structural characterization of active human cGAS-DNA complexes before therapeutic design, establishing the structural basis for human-specific regulation. This preliminary structural information enables subsequent rational drug design that targets the active conformation specific to human cGAS, rather than relying on inactive or homologous structures.
Solution Approach 2:
The patent identifies specific amino acid substitutions (K187N and L195R) that change the structural and functional parameters of human cGAS compared to mouse cGAS. These parameter changes in the protein sequence lead to distinct DNA-binding specificities and regulatory controls, enabling structure-guided therapeutics that exploit human-specific features.
2Productivity
If human cGAS enzymatic potential is increased to match other mammalian homologs, then DNA-sensing sensitivity is improved, but autoimmunity risk increases due to disrupted tolerance to self-DNA
Solution Approach 1:
The patent identifies specific local regions in the cGAS protein structure where human-specific amino acid substitutions (K187 and L195) occur. These localized structural differences create distinct DNA-binding interfaces that confer human-specific regulatory control, allowing enhanced enzymatic activity in response to pathogen DNA while maintaining tolerance to self-DNA through context-dependent activation mechanisms.
Solution Approach 2:
The patent suggests that human cGAS operates with feedback control mechanisms that regulate enzymatic activity based on the specific DNA context and cellular conditions. The structural differences identified provide a basis for feedback regulation that prevents constitutive activation and autoimmunity while maintaining the ability to respond appropriately to viral infections.
3Ease of manufacture
If structural information for active human cGAS-DNA complex is obtained, then therapeutic design is enabled, but this requires overcoming the limitation that no such structure currently exists
Solution Approach 1:
The patent performs preliminary structural characterization of the active human cGAS-DNA complex through crystallography or NMR, obtaining the first high-resolution structure of this biologically relevant complex. This preliminary structural data is then made available for therapeutic design, eliminating the need for complex computational modeling or inference from inactive structures.
Solution Approach 2:
The patent uses structural information from mouse cGAS-DNA complexes as a starting point for understanding human cGAS structure, then refines this copy by identifying and accounting for human-specific amino acid substitutions. This approach allows structural characterization of the difficult-to-obtain active human complex by leveraging the well-characterized mouse structure while incorporating human-specific features.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The elucidation of human cGAS structure and regulatory mechanisms allows for the development of modified polypeptides with enhanced 2′3′ cGAMP synthesis, improved DNA-length specificity, and stabilized enzyme conformation, facilitating the design of targeted therapeutics for immune responses and diseases.
Implementation Method 1
cGAS is a direct innate immune sensor that binds double-stranded DNA and catalyzes production of the second messenger 2′-5′/3′-5′ cyclic GMP-AMP (2′3′ cGAMP)
Implementation Method 2
2′3′ cGAMP then activates the receptor Stimulator of Interferon Genes (STING) to initiate a downstream transcription cascade and type I interferon signaling
Data Source
AI summary
The present invention is based, in part, on the discovery of the human-specific regulatory control of cGAS and the structure of the active human cGAS-DNA complex, as well as compositions comprising the modified hcGAS polypeptide, hcGAS-DNA complex, hcGAS-DNA-ATP complex, and methods of screening for modulators of the structure, expression, and/or activity of such polypeptides and complexes.